Lactate-Depleting Engineered Probiotics Remodel the Tumor Microenvironment and Enhance PD-1 Blockade.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42226474.
- Also identified by DOI 10.1002/adhm.71316.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
High lactate concentrations in the tumor microenvironment (TME) suppress antitumoral immunity. Although modulating intratumoral lactate is a promising strategy, tumor-targeted interventions remain limited. Here, we developed an engineered probiotic, Lac-EcN, capable of targeted lactate consumption within the TME. Lac-EcN reduces intratumoral lactate levels by over 60% and alleviates tumor acidosis, accompanied by reversal of aberrant NFAT1 nuclear translocation in Tregs and restoration of effector molecule production by cytotoxic T cells. In B16-F10 melanoma and MC-38 colorectal carcinoma models, Lac-EcN combined with anti-PD-1 improves tumor inhibition and extends survival. These results position engineered probiotics as a platform for targeted metabolic intervention in the TME, integrating metabolic reprogramming with immune checkpoint blockade.